Medtronic has finalized its acquisition of CathWorks, a medical device company focused on advancing the diagnosis and treatment of coronary artery disease (CAD), for a base price of $585 million. The deal, announced on April 20, 2026, marks the second tuck-in acquisition completed by Medtronic this year as part of its strategy to strengthen its cardiovascular portfolio through targeted investments in innovative technologies.
The acquisition follows a strategic partnership established in 2022, during which Medtronic and CathWorks co-promoted the FFRangio® System in the United States, Europe, and Japan. CathWorks’ FFRangio® System uses artificial intelligence and computational science to generate fractional flow reserve (FFR) values from routine, drug-free, wire-free coronary angiograms, enabling a comprehensive physiological assessment of the entire coronary tree without the need for invasive pressure wires.
According to Medtronic’s official press release, the transaction includes potential undisclosed earn-out payments contingent on future performance milestones. The company stated that the acquisition aligns with its broader innovation strategy to accelerate growth in high-growth areas close to commercialization, particularly within its interventional cardiology and cardiovascular portfolios.
Jason Weidman, senior vice president and president of Medtronic’s Coronary & Renal Denervation business, emphasized the strategic value of the deal, noting that the collaboration had already demonstrated how CathWorks’ technology could disrupt traditional wire-based FFR assessments by leveraging data and AI to support physicians throughout a patient’s journey—from diagnosis to treatment.
Ramin Mousavi, president and chief executive officer of CathWorks, described the acquisition as a testament to the shared vision between the two companies to revolutionize the cath lab and improve outcomes for patients living with cardiovascular disease. He highlighted that the integration of CathWorks’ technology into Medtronic’s global infrastructure would help usher in a modern era of cardiovascular diagnosis.
The FFRangio® System analyzes standard angiographic images using advanced computational models to estimate blood flow and pressure differences across coronary lesions, providing clinicians with functional insights that complement anatomical imaging. This approach aims to reduce procedural time, minimize patient discomfort, and lower the risk associated with wire-based FFR measurements, which require the insertion of a pressure sensor into the coronary artery.
Medtronic’s move to acquire CathWorks reflects a broader trend in the medical technology industry toward integrating AI-driven diagnostic tools into existing imaging workflows. By embedding physiological assessment capabilities directly into angiographic analysis, companies aim to enhance clinical decision-making while streamlining cath lab operations.
The acquisition was first announced in February 2026, when Medtronic revealed its intent to exercise an option to acquire CathWorks under the terms of their 2022 partnership agreement. At that time, the company noted that the deal would bolster its interventional cardiology offerings and expand its leadership in transforming how cardiovascular disease is diagnosed and treated.
Medtronic has too pursued other strategic investments in early 2026, including a $550 million agreement to acquire Scientia Vascular, a developer of neurovascular navigation technology, and a commitment to invest up to $90 million in Anteris Technologies, which focuses on transcatheter aortic valve replacement (TAVR) devices. These moves underscore the company’s focus on tuck-in acquisitions that complement its core businesses in cardiovascular and neuroscience.
Industry analysts have noted that Medtronic’s increased M&A activity signals a shift toward accelerating innovation through external partnerships rather than relying solely on internal research and development. The company’s leadership has stated that targeting commercially ready, high-growth technologies allows for faster integration and quicker realization of clinical and commercial benefits.
For patients, the wider availability of non-invasive FFR assessment tools like the FFRangio® System could lead to more accessible and safer evaluation of coronary artery disease, particularly in settings where invasive physiological testing may be impractical or unavailable. The technology may also support more accurate identification of functionally significant lesions, helping guide decisions about stent placement or medical therapy.
Healthcare providers may benefit from reduced procedural complexity and shorter lab times, potentially increasing cath lab throughput and improving resource utilization. The wire-free nature of the technology also eliminates the need for specialized training associated with pressure wire handling, which could broaden adoption across diverse clinical environments.
As of the closing date, Medtronic has not disclosed specific timelines for integrating CathWorks’ operations or rolling out the FFRangio® System under its global commercial infrastructure. Yet, given the existing co-promotion agreement, the transition is expected to build on established distribution channels in key markets.
Officials from both companies have indicated that the acquisition will preserve CathWorks’ commitment to innovation while leveraging Medtronic’s scale to expand access to its technology. No workforce reductions or operational disruptions have been reported in connection with the deal.
Medtronic’s next scheduled update on its acquisition strategy and financial performance is expected during its quarterly earnings call, which historically occurs in late July. Shareholders and analysts will likely seek further detail on how the CathWorks integration is progressing and its early impact on revenue and product development pipelines.
For authoritative information on Medtronic’s acquisitions, investors and medical professionals can refer to the company’s official press releases, SEC filings, and presentations from investor conferences such as the J.P. Morgan Healthcare Conference. Updates on CathWorks’ technology and clinical applications are also available through peer-reviewed journals and medical device regulatory databases.
If you found this overview of Medtronic’s acquisition of CathWorks informative, consider sharing it with colleagues or peers interested in medical innovation, cardiovascular care, or health technology trends. We welcome thoughtful comments and discussions on how advancements like AI-powered diagnostic tools are shaping the future of patient care.